Y-MABS THERAPEUTICS I

Y-mAbs’ Announces Clearance of IND for GD2-SADA

12 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

31 May 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

26 May 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

09 May 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

03 May 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

27 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of SADA Technology at AACR

08 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

01 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

24 Feb 2022 15:01:01 By Nasdaq GlobeNewswire

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

17 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

11 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

UPDATE - Y-mAbs Announces Pipeline Update

15 Dec 2021 08:53:41 By Nasdaq GlobeNewswire

Y-mAbs Announces Pipeline Update

15 Dec 2021 08:00:02 By Nasdaq GlobeNewswire

Y-mAbs Hosting Virtual Research and Development Day

06 Dec 2021 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments

04 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis

04 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

28 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at SIOP 2021

16 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

13 Sep 2021 08:00:01 By Nasdaq GlobeNewswire